Condition: Non-small Cell Lung Cancer · Esophageal Cancer · Gastric Cancer · Sponsor: University of Missouri-Columbia
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery. Circulating and disseminated tumor cell (CTC/DTC) and circulating cell-free (cf) DNA isolation from the blood, urine and bone marrow will increase understanding of cancer spread and advance knowledge to develop individualized therapies.
This description comes directly from the study's public registry record.
Jussuf T Kaifi, MD, PhD · 5738828445 · kaifij@health.missouri.edu
Blanche Lasta, RN · 5738828445 · lastal@health.missouri.edu
Always discuss trial participation with your own doctor first.
| Ellis Fischel Cancer Center, University of Missouri | Columbia, Missouri, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02838836